🇺🇸 FDA
Pipeline program

CEA protein antigen plus BCG Vaccine Mix for percutaneous use

IND 009549

Phase 1 mab active

Quick answer

CEA protein antigen plus BCG Vaccine Mix for percutaneous use for Rectal Cancer is a Phase 1 program (mab) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Rectal Cancer
Phase
Phase 1
Modality
mab
Status
active

Clinical trials